AstraZeneca investors react badly to CEO bonus payment plan

Nearly 40% of shareholders voted against the proposal to hand chief executive Pascal Soriot pay and perks of nearly €21m for 2021

Covid-19 vaccine developer AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive Pascal Soriot bigger bonus awards for the second consecutive year

Covid-19 vaccine developer AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive Pascal Soriot bigger bonus awards for the second consecutive year.

Nearly 40% voted against the policy, which could hand him pay and perks of nearly £18m (€21m) for 2021.